



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

APE1-IN-1

Cat. No.:	HY-136731		
CAS No.:	524708-03-0		
Molecular Formula:	C ₁₉ H ₂₁ N ₃ OS ₂		
Molecular Weight:	371.52		
Target:	DNA/RNA Synthesis		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 22 mg/mL (59.22 mM; ultrasonic and warming and heat to 80°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.6916 mL	13.4582 mL	26.9165 mL
	5 mM		0.5383 mL	2.6916 mL	5.3833 mL
	10 mM		0.2692 mL	1.3458 mL	2.6916 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/aprimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC₅₀ value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and [Temozolomide](#) (HY-17364) to cancer cells^[1].

IC₅₀ & Target

IC₅₀: 2 μM (APE1)^[1]

In Vitro

APE1-IN-1 (compound 3) exhibits an IC₅₀ of 2 μM in the qHTS assay and an IC₅₀ of 12 μM in a radiotracer incision assay (RIA)^[1].

APE1-IN-1 (0, 1, 3, 10, 30, or 100 μM; 15 min) inhibits HeLa whole cell extract AP site incision in a dose-dependent manner^[1]. APE1-IN-1 (5-30 μM; 24 h) exhibits cytotoxic activity against HeLa cells, and potentiates the activity of methyl methanesulfonate and [Temozolomide](#) (HY-17364)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	HeLa cells
Concentration:	5-30 μ M
Incubation Time:	24 h
Result:	Exhibited cytotoxic activity against HeLa cells with a 50% reduction in cell viability occurring at $\sim$ 15 μ M. Greatly potentiated the activity of methyl methanesulfonate (0.4 mM) and Temozolomide (HY-17364) (1 mM) with optimal synergy occurring at $\sim$ 5 μ M and $\sim$ 10 μ M, respectively.

In Vivo

APE1-IN-1 (30 mpk; IP; single dosage) exhibits favorable pharmacokinetic property^[1].
Pharmacokinetic Parameters of APE1-IN-1 (compound 3) (IP; 30 mpk) in CD1 mice^[1].

	Plasma	Brain
$t_{1/2}$ (h)	2.1	1
brain/plasma	21	
C_{max} (μ M)	16	217
t_{max} (h)	0.25	0.25
CLogP	2.83	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CD1 male mice (n = 3) ^[1]
Dosage:	30 mpk
Administration:	IP; single dosage
Result:	Showed lipophilic (CLogP = 2.8), crossed the BBB quite readily, giving rise to a B/P ratio of 21.

REFERENCES

[1]. Rai G, et al. Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/aprimidinic endonuclease 1 inhibitors. J Med Chem. 2012 Apr 12;55(7):3101-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA